KALA
KALA BIO, Inc.
Next earnings Aug 6, 2026 (before open) · consensus $-0.30 EPS
$2.52
▼ -1.18%$2.52▼ -98.75%
over 1Y
L $2.06EODHDH $981.50
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.2%
1W-28.8%
1M+8.2%
3M-71.3%
YTD-91.9%
1Y-98.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity 0.36x).
KALA BIO, Inc. shows $0.00 in FY2025 revenue, and -385.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $3.89M | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$130M | -$81.7M | -$39.7M | -$41.0M | -$39.2M |
| Net income | -$143M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Diluted EPS | -$108.32 | -$29.48 | -$17.35 | -$10.15 | -$3.31 |
| Net margin | -1268.7% | -1151.6% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.37B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.2%
FCF yield-1.4%
Quality & risk
ROIC (est.)-82.6%
Free cash flow-$33.3M
Total debt$30.4M
Net cash-$22.9M
Altman Z-Score448.26 safe
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+14305.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
- S-3/A Shelf registration (potential raise)2026-06-12
- 10-Q Quarterly report2026-05-15
- 8-K Material event2026-05-07
- S-3 Shelf registration (potential raise)2026-05-07
- 10-K Annual report2026-04-15
- NT 10-K Late filing notice2026-03-31
- 8-K Material agreement2026-03-04
- 8-K Officer / director change2026-02-20
- S-3 Shelf registration (potential raise)2026-02-10
Recent filings
all on EDGAR ↗EFFECTFiling2026-06-25open ↗S-3/AFiling2026-06-12open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-15open ↗S-3Filing2026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗10-KPeriod ending 2025-12-312026-04-15open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗DFiling2026-03-17open ↗144Filing2026-03-17open ↗144Filing2026-03-12open ↗144Filing2026-03-12open ↗
Frequently asked
- Is KALA BIO, Inc. (KALA) a buy?
- KALA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.36x).
- What is KALA BIO, Inc.'s quality score?
- KALA scores 57.00000000000001/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001479419, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 9:49:30 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.